EF13 data

The Surrey, U.K., company published evidence of extended survival in an Indian trial in 15 patients. As reported in Cancer Letters, the patients, with Grade III or IV astrocytomas or glioblastomas, received a daily infusion of the agent into the surgical cavity for 10 days after removal of the tumor, and had brain scans before and after the treatment.

Only 3 of the 15 patients died on two-year follow-up; the rest have no evidence of tumor recurrence. Typical survival is 20 percent after two years with surgery followed by radiotherapy. ...